tradingkey.logo
tradingkey.logo

Spyre Announces Acceleration Of Expected Topline Readout Of Skyway Rheumatoid Arthritis Sub-Study To Q3 2026

ReutersMar 16, 2026 12:13 PM

- Spyre Therapeutics Inc SYRE.O:

  • SPYRE ANNOUNCES ACCELERATION OF EXPECTED TOPLINE READOUT OF SKYWAY RHEUMATOID ARTHRITIS SUB-STUDY TO Q3 2026

  • SPYRE THERAPEUTICS INC - PSA AND AXSPA SUB-STUDY RECRUITMENT ON TRACK; TOPLINE DATA EXPECTED Q4 2026

  • SPYRE THERAPEUTICS INC - SKYLINE UC TRIAL ENROLLING AHEAD OF SCHEDULE; PART A READOUTS BEGIN Q2 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI